資源描述：
《egfr-tkis治療egfr突變陽性的晚期非小細胞肺腺癌的臨床研究》由會員上傳分享，免費在線閱讀，更多相關內容在學術論文-天天文庫。
1、授予單位代碼10089___學號或申請?zhí)?0132424_中國圖書分類號R734___HebeiMedicalUniversity碩士學位論文科學學位EGFR-TKIs治療EGFR突變陽性的晚期非小細胞肺腺癌的臨床研究研究生：孫紅娜導師：丁翠敏教授專業(yè)：內科學二級學院：河北醫(yī)科大學第四醫(yī)院2013年10月～2016年2月萬方數據河北醫(yī)科大學學位論文使用授權及知識產權歸屬承諾本學位論文在導師（或指導小組）的指導下，由本人獨立完成。本學位論文研究所獲得的研究成果，其知識產權歸河北醫(yī)科大學所有。河北醫(yī)科大學有權對本學位論文進行交流、公開和使用。凡發(fā)表與學位論文主要內容相關的論文，第一署名為單
2、位河北醫(yī)科大學，試驗材料、原始數據、申報的專利等知識產權均歸河北醫(yī)科大學所有。否則，承擔相應法律責任。研究生簽名：導師簽章：二級學院領導蓋章：年月日河北醫(yī)科大學研究生學位論文獨創(chuàng)性聲明本論文是在導師指導下進行的研究工作及取得的研究成果，除了文中特別加以標注和致謝等內容外，文中不包含其他人已經發(fā)表或撰寫的研究成果，指導教師對此進行了審定。本論文由本人獨立撰寫，文責自負。研究生簽名：導師簽章：年月日萬方數據目錄中文摘要·············································································1英文摘要·····
3、········································································4英文縮寫·············································································8研究論文EGFR-TKIs治療EGFR突變陽性的晚期非小細胞肺腺癌的臨床研究前言·············································································9材料與方法··················
4、··················································11結果·············································································14附圖·············································································16附表·············································································21討
5、論·············································································26結論·············································································31參考文獻·······································································32綜述晚期非小細胞肺癌靶向治療進展······································35致謝
6、···················································································52個人簡歷·············································································53萬方數據中文摘要EGFR-TKIs治療EGFR突變陽性的晚期非小細胞肺腺癌的臨床研究摘要目的：肺癌（LungCancer）是目前全球最高發(fā)的惡性腫瘤之一。在我國，肺癌的發(fā)病率和死亡率也與全球發(fā)展趨勢相似，呈逐年上升趨勢。其中非小細胞肺癌（NonSmallC
7、ellLungCancer,NSCLC）占肺癌比例最大，約占80%以上。對于早期的非小細胞肺癌患者，可以行手術治療，術后的5年生存率最高可達50%。但大部分肺癌患者發(fā)現即為晚期，失去了手術機會，無法行手術切除。因此對于晚期非小細胞肺癌，化療、放療、分子靶向治療成為主要方式，其中以鉑類為基礎聯合第三代化療藥物的治療方案仍是目前的一線標準方案，雖能延長患者的生存，但副反應大，效果仍欠佳。而EGFR-TKIs的問世，讓臨床醫(yī)生眼前為之一亮，使現有的臨
